The Karma research group at Karolinska Institutet is creating the world’s best-characterised breast cancer cohort. The aim is to reduce the mortality and incidence in breast cancer through translational research focusing on breast cancer screening and prevention.

READ MORE ABOUT THE KARMA STUDY

The Karma research group at Karolinska Institutet is creating the world’s best-characterised breast cancer cohort. The aim is to reduce the mortality and incidence in breast cancer through translational research focusing on breast cancer screening and prevention.

READ MORE ABOUT THE KARMA STUDY

Recent news

2026-05-04

New treatment with fewer side effects reduces breast density

Low doses of the investigational medicinal product endoxifen reduce breast density to the same extent as the standard treatment tamoxifen, but without causing such troublesome side effects. This is shown by a new study from Karolinska Institutet published in the Journal of the National Cancer Institute. The results may have implications for future preventive treatment...
2025-04-01

Full rollout of SMART

After piloting for feasibly in 2024, the SMART trial (Stockholm MAmmography Risk stratified Trial) is now in full recruitment mode. Including two main hospitals, Södersjukhuset and Capio St Göran, in the Stockholm area, covering ≈ 70% of all women included in the mammography screening program in Stockholm. SMART will recruit a total of 46 000...
2024-06-03

SMART supported by Atossa Therapeutics Inc

SMART (Stockholm MAmmography Risk stratified Trial) is a phase 2 study conducted at the mammography unit at Södersjukhuset (Stockholm South General Hospital), Sweden. The purpose of the study is to test if individualized, risk-based breast cancer screening is superior to current practice in Sweden. In SMART we will test if an individualized, imaging-based AI screening...
More news
LOG IN

Log in to the Karma Research Platform here

Not a member? REGISTER HERE...
Interview

Professor Per Hall talks about Karma

See the interview (in Swedish)